Drug research

Tildacerfont

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as SPR001

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAHNCT05128942	Spruce Biosciences	Phase 2	Terminated	2025-01-31Actual
A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal AndrogensNCT05370521	Spruce Biosciences	Phase 2	Terminated	2023-08-03Actual

Spruce BiosciencesTerminatedPrimary completion: 2025-01-31 · Actual

Trial details

Spruce BiosciencesTerminatedPrimary completion: 2023-08-03 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.